17 Nov 2017 17:22
17 November 2017
AGM Resolutions
On 12 October 2017 Clinigen Group plc (AIM:CLIN, "Clinigen" or "the Group") published the Notice convening the Group's 2017 Annual General Meeting ("AGM"), which is to be held on 28 November 2017 at 10.00am. Also on 12 October 2017, this Notice, and a letter from the Chairman, were posted to shareholders, accompanied by a copy of the 2017 Annual Report.
Clinigen confirms that, consistent with the statement made in the Remuneration Report contained within the 2017 Annual Report, it is intended that at the forthcoming AGM the Group's remuneration policy, as set out in the Remuneration Report, will be put forward, on an advisory basis, for shareholder approval. Shareholders who wish to vote on the Group's remuneration policy will need to attend the AGM and vote in person.
- Ends-
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer | |
Matt Parrish, Head of Investor Relations | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com